Comment
doi: 10.1016/j.cell.2009.05.011.
Finding and drugging the vulnerabilities of RAS-dependent cancers
Affiliations
- PMID: 19490885
- DOI: 10.1016/j.cell.2009.05.011
Item in Clipboard
Comment
Finding and drugging the vulnerabilities of RAS-dependent cancers
Cell.
.
Free article
Abstract
Kinase inhibitors have ushered in the era of targeted therapy, but their utility to date is primarily limited to cancers bearing oncogenic kinase mutations. Two papers in this issue (Luo et al., 2009; Scholl et al., 2009) could change this landscape by uncovering kinase-specific vulnerabilities in tumors with RAS mutations.
Comment on
-
Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells.Cell. 2009 May 29;137(5):821-34. doi: 10.1016/j.cell.2009.03.017. Cell. 2009. PMID: 19490892
-
A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene.Cell. 2009 May 29;137(5):835-48. doi: 10.1016/j.cell.2009.05.006. Cell. 2009. PMID: 19490893 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
